Zobrazeno 1 - 10
of 225
pro vyhledávání: '"E. Micillo"'
Autor:
Luigi Maiorino, Giuseppe De Cataldis, G.P. Nicolella, Vito Lorusso, A Lamberti, R. Cioffi, Angelo Di Nota, Giuseppe Frasci, S. Mancarella, E. Micillo, Pasquale Comella, Domenico Bilancia, N. Panza, Luigi Manzione, Michele Di Natale, Giuseppe Comella
Publikováno v:
Clinical Lung Cancer. 1:202-207
In a previous phase II randomized study, a cisplatin/gemcitabine/vinorelbine (PGV) regimen produced a 50-week median survival time (MST) in advanced non–small-cell lung cancer (NSCLC) patients. The present trial was planned to randomly compare the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::706ccae4a7957e34b0bbf602fe0ed78e
https://doi.org/10.3816/clc.2000.n.003
https://doi.org/10.3816/clc.2000.n.003
Autor:
O. Orlandi, G. de Iola, P. Mangiarotti, E. Micillo, F. Ginesu, M Gori, M. Onoscuri, M. Lucchini, E. Catena, Carlo Grassi
Publikováno v:
Journal of Antimicrobial Chemotherapy. 26:103-110
To determine the efficacy and safety of pefloxacin in the treatment of lower respiratory tract infections, a multicentre trial involving four departments of respiratory diseases was performed. One hundred and eight patients were admitted to the study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c583991d7a31be8e06a5626646506d4
https://doi.org/10.1093/jac/26.suppl_b.103
https://doi.org/10.1093/jac/26.suppl_b.103
Alveolar macrophages (A.M.) are the main resi¬dent phagocytes in the human lung, and play a nayor role in local defence against environmen¬tal agents. Stimulation of these cells by dif-ferent stimula (antigen,LPS etc.) induces the release of a larg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3977::9f1c225de6bc0fd723930114cadda33c
http://hdl.handle.net/11591/222085
http://hdl.handle.net/11591/222085
Autor:
N. Panza, Giuseppe De Cataldis, Michele Di Natale, Pasquale Comella, Giuseppe Frasci, Gaetano Di Rienzo, Gianfranco Filippelli, Domenico Bilancia, R. Cioffi, A Lamberti, Giuseppe Comella, Luigi Maiorino, Angelo Di Nota, G.P. Nicolella, Luigi Manzione, E. Micillo, Vito Lorusso
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 18(7)
PURPOSE: In our previous phase II study, the cisplatin, gemcitabine, and vinorelbine (PGV) regimen produced a median survival time (MST) of approximately 1 year in advanced non–small-cell lung cancer (NSCLC) patients. The present study was aimed at
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f3cdc16335b5185a57d0790f6d9ed66
https://pubmed.ncbi.nlm.nih.gov/11208856
https://pubmed.ncbi.nlm.nih.gov/11208856
Autor:
G, Frasci, N, Panza, P, Comella, G P, Nicolella, M, Natale, L, Manzione, D, Bilancia, R, Cioffi, L, Maiorino, G, De Cataldis, M, Belli, E, Micillo, V, Mascia, B, Massidda, V, Lorusso, M, De Lena, F, Carpagnano, A, Contu, G, Pusceddu, G, Comella
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 17(8)
Because both cisplatin-paclitaxel and cisplatin-gemcitabine combinations are generally considered to be among the most active regimens in non-small-cell lung cancer (NSCLC) patients, this study aimed to determine the maximum-tolerated dose (MTD) of p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b04f84c52a4b0ef5a0bebe8b804ffb97
https://pubmed.ncbi.nlm.nih.gov/10561293
https://pubmed.ncbi.nlm.nih.gov/10561293
Autor:
Pasquale Comella, Giuseppe Comella, J. Perchard, R. Cioffi, Edoardo Biondi, Dario Nicolella, Carlo Curcio, E. Micillo, N. Panza, Giuseppe De Cataldis, Giuseppe Frasci, Giovanni Pietro Ianniello
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 15(1)
Seventy previously untreated patients with advanced NSCLC were randomised, after stratification for stage (IIIB vs. IV) and Performance Status (0-1 vs. 2), to receive either treatment A: CDDP 40 mg/m2 + VP16 100 mg/m2 day 1-3 (37 patients); or treatm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65add87df9afeb98c0b9644c743d1556
https://pubmed.ncbi.nlm.nih.gov/8865128
https://pubmed.ncbi.nlm.nih.gov/8865128
Autor:
E, Micillo
Publikováno v:
Archivio Monaldi per le malattie del torace. 46(1-6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9a882874eb89b7fda68cea413db54a51
https://pubmed.ncbi.nlm.nih.gov/1845423
https://pubmed.ncbi.nlm.nih.gov/1845423
Publikováno v:
Archivio Monaldi per le malattie del torace. 45(1)
In this study, some hemorheological and coagulative parameters (blood viscosity, erythrocyte filtrability, CPA, platelet aggregation) have been evaluated in 40 patients with Chronic Respiratory Failure. The results obtained document in these patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::132276676f826db75f73b8a738bc8dab
https://pubmed.ncbi.nlm.nih.gov/1669259
https://pubmed.ncbi.nlm.nih.gov/1669259
Publikováno v:
Archivio Monaldi per le malattie del torace. 45(1)
Pefloxacin is an antibacterial agent belonging to the group of quinolones having a methyl-carboxylic acid which possesses a high activity as compared to other quinolonic drugs. In this study we tested the efficacy and tolerability of the drug in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0dfcafa11baa59514f9472488adc1b06
https://pubmed.ncbi.nlm.nih.gov/1669257
https://pubmed.ncbi.nlm.nih.gov/1669257